Abstract

B cell dysfunction due to obesity can be associated with alterations in the levels of micro-RNAs (miRNAs). However, the role of miRNAs in these processes remains elusive. Here, we show that miR-802 is increased in the pancreatic islets of obese mouse models and demonstrate that inducible transgenic overexpression of miR-802 in mice causes impaired insulin transcription and secretion. We identify Foxo1 as a transcription factor of miR-802 promoting its transcription, and NeuroD1 and Fzd5 as targets of miR-802-dependent silencing. Repression of NeuroD1 in β cell and primary islets impairs insulin transcription and reduction of Fzd5 in β cell, which, in turn, impairs Ca2+ signaling, thereby repressing calcium influx and decreasing insulin secretion. We functionally create a novel network between obesity and β cell dysfunction via miR-802 regulation. Elucidation of the impact of obesity on microRNA expression can broaden our understanding of pathophysiological development of diabetes.

Obesity predisposes to type 2 diabetes, but the mechanisms of obesity-associated β cell dysfunction are incompletely understood. Here the authors report that obesity increases the levels of miR-802, which impairs insulin transcription and secretion by targeting NeuroD1 and Fzd5.

Details

Title
Obesity-induced overexpression of miR-802 impairs insulin transcription and secretion
Author
Zhang, Fangfang 1   VIAFID ORCID Logo  ; Ma Dongshen 2 ; Zhao, Wanli 3 ; Wang Danwei 1 ; Liu Tingsheng 1 ; Liu, Yuhong 1 ; Yang, Yue 1 ; Liu, Yue 1 ; Mu Jinming 1 ; Li, Bingbing 1 ; Zhang, Yanfeng 1 ; Pan, Yi 1 ; Guo Changying 1 ; Du, Hong 4 ; Li, Ling 5 ; Fu Xianghui 6   VIAFID ORCID Logo  ; Cao Zhengyu 3   VIAFID ORCID Logo  ; Liang, Jin 1 

 State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, School of life Science and Technology, China Pharmaceutical University. 24 Tongjiaxiang, Jiangsu province, Nanjing, PR China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793) 
 State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, School of life Science and Technology, China Pharmaceutical University. 24 Tongjiaxiang, Jiangsu province, Nanjing, PR China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793); Department of Pathology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China (GRID:grid.413389.4) 
 Jiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, PR China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793) 
 Department of Endocrinology, Nanjing Jinling Hospital. 305 Zhongshan East Road, Nanjing, PR China (GRID:grid.254147.1) 
 Department of Endocrinology, School of Medicine, Zhongda Hospital, Southeast University, 87 DingJiaQiao Rd, Nanjing, Nanjing, PR China (GRID:grid.263826.b) (ISNI:0000 0004 1761 0489) 
 Division of Endocrinology and Metabolism, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, China (GRID:grid.412901.f) (ISNI:0000 0004 1770 1022) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2389724974
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.